99 related articles for article (PubMed ID: 26485776)
21. Desmoplastic melanoma: an updated immunohistochemical analysis of 40 cases with a proposal for an additional panel of stains for diagnosis.
Plaza JA; Bonneau P; Prieto V; Sangueza M; Mackinnon A; Suster D; Bacchi C; Estrozi B; Kazakov D; Kacerovska D; Falconieri G; Suster S
J Cutan Pathol; 2016 Apr; 43(4):313-23. PubMed ID: 26661921
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
23. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
24. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas.
Tacha D; Qi W; Ra S; Bremer R; Yu C; Chu J; Hoang L; Robbins B
Arch Pathol Lab Med; 2015 Apr; 139(4):530-6. PubMed ID: 25436903
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
26. Absence of V599E BRAF mutations in desmoplastic melanomas.
Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of BRAF and NRAS mutations in fast-growing melanomas.
Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D
Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684
[No Abstract] [Full Text] [Related]
28. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.
Lang J; MacKie RM
J Invest Dermatol; 2005 Sep; 125(3):575-9. PubMed ID: 16117801
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma.
Choy B; Hyjek E; Montag AG; Pytel P; Haydon R; Luu HH; Zhen CJ; Long BC; Kadri S; Segal JP; Furtado LV; Cipriani NA
Histopathology; 2017 Apr; 70(5):734-745. PubMed ID: 27926791
[TBL] [Abstract][Full Text] [Related]
32. SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics.
Palla B; Su A; Binder S; Dry S
Am J Dermatopathol; 2013 Jul; 35(5):576-81. PubMed ID: 23291581
[TBL] [Abstract][Full Text] [Related]
33. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
34. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
35. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
36. Varying Mutational Alterations in Multiple Primary Melanomas.
Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
[TBL] [Abstract][Full Text] [Related]
37. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma.
Hilliard NJ; Krahl D; Sellheyer K
J Cutan Pathol; 2009 Jul; 36(7):753-9. PubMed ID: 19519606
[TBL] [Abstract][Full Text] [Related]
38. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
39. Expression of TLE1 in Malignant Melanoma With Spindle Cell Morphology: A Potential Diagnostic Pitfall.
Morrell TJ; Xiong Y; Deng A; Dresser K; O'Donnell P; Cornejo KM
Int J Surg Pathol; 2019 May; 27(3):259-262. PubMed ID: 30301396
[TBL] [Abstract][Full Text] [Related]
40. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
Vízkeleti L
Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]